Perspectives on cancer experiences with oncologist Dr. Willie Goffney

American Cancer Society

Share This Post

Feb 2023: Check out this tweet from American Cancer Society that shares conversation with Dr. Willie Goffney about perspective on cancer. Tweet says “Join Adam Lopez, host of Candid Conversations, as he discusses personal and professional perspectives on cancer experiences with oncologist Dr. Willie Goffney and community leader Tracie Kimbrough as part of the ongoing Diversity in Science campaign.” Check out thus tweet from ACC below.

You can also watch the entire conversation on YouTube.


Check out the entire conversation on YouTube.

The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. We are the only organization working to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer. Learn more about who we are, what we do, and our plans for the future by exploring the areas below.

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (1). The most common in 2020 (in terms of new cases of cancer) were:

  • breast (2.26 million cases);
  • lung (2.21 million cases);
  • colon and rectum (1.93 million cases);
  • prostate (1.41 million cases);
  • skin (non-melanoma) (1.20 million cases); and
  • stomach (1.09 million cases).

The most common causes of cancer death in 2020 were:

  • lung (1.80 million deaths);
  • colon and rectum (916 000 deaths);
  • liver (830 000 deaths);
  • stomach (769 000 deaths); and
  • breast (685 000 deaths).

Each year, approximately 400 000 children develop cancer. The most common cancers vary between countries. Cervical cancer is the most common in 23 countries. 

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/